28 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary results LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its maiden audited preliminary results for the year ended 31 December 2021, following admission to trading on AIM on 8 July 2021. Summary and Highlights for the year: Revenues […]
17 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Veterans Affairs (VA) sites added to validation study with first Veteran enroled Key lung cancer specialist, Dr Drew Moghanaki, appointed to Scientific Advisory Board LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its pivotal clinical study to evaluate the […]
LungLife AI licensure/accreditation information posted here.